Skip to main content
SpringerLink
Log in

Melatonin and the Metabolic Syndrome

  • Chapter
  • First Online:
Melatonin and Melatonergic Drugs in Clinical Practice

Abstract

The ongoing worldwide obesity epidemic is paralleled by an elevated incidence of the metabolic syndrome, a disorder referred to as a clustering of metabolic abnormalities that increase the risk for cardiovascular disease and type 2 diabetes. Considered as a multifunctional molecule, the pineal gland hormone melatonin is also involved in body fat mass and energy metabolism regulation. A large body of evidence supports the beneficial effects of melatonin on the cardiovascular function in normal and pathophysiological conditions. However, melatonin’s role in cardiovascular risk factors such as obesity and other related disorders including the metabolic syndrome needs further investigations, particularly in humans. This chapter will address the effects of melatonin on the metabolic syndrome focusing on obesity and insulin-resistant conditions. Since cardiovascular disease is the primary outcome of the metabolic syndrome, the effects of melatonin on cardiovascular function will be also described focusing on normal and pathological conditions. In view of the current knowledge, we aim to reveal the potential clinical relevance of melatonin or melatonin receptor agonists in the setting of obesity-induced metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804–14.

    PubMed  Google Scholar 

  2. de Onis M, Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr. 2010;92:1257–64.

    PubMed  Google Scholar 

  3. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377:557–67.

    PubMed  Google Scholar 

  4. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629–36.

    CAS  PubMed  Google Scholar 

  5. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40.

    CAS  PubMed  Google Scholar 

  6. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJV. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15000 middle-aged men and women (the Renfrew–Paisley study). Eur Heart J. 2006;27:96–106.

    CAS  PubMed  Google Scholar 

  7. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7:279–88.

    CAS  PubMed  Google Scholar 

  8. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J, James WPT, Loria CM, Smith SC. Harmonizing the metabolic syndrome. Circulation. 2009;120:1640–5.

    CAS  PubMed  Google Scholar 

  9. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, Juneja A. Non-alcoholic fatty liver disease (NAFLD)–the hepatic component of metabolic syndrome. J Assoc Physicians India. 2009;57:201–4.

    Google Scholar 

  10. Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG. The complex interaction between obesity, metabolic syndrome and reproductive axis: A narrative review. Metabolism. 2013;62:457–78.

    CAS  PubMed  Google Scholar 

  11. Wolk R, Somers VK. Sleep and the metabolic syndrome. Exp Physiol. 2007;92:67–78.

    PubMed  Google Scholar 

  12. Ruan X, Guan Y. Metabolic syndrome and chronic kidney disease. J Diabetes. 2009;1:236–45.

    CAS  PubMed  Google Scholar 

  13. Katz JD, Agrawal S, Velasquez M. Getting to the heart of the matter: osteoarthritis takes its place as part of the metabolic syndrome. Curr Opin Rheumatol. 2010;22:512–9.

    PubMed  Google Scholar 

  14. Pietropaoli D, Monaco A, Del Pinto R, Cifone MG, Marzo G, Giannoni M. Advanced glycation end products: possible link between metabolic syndrome and periodontal diseases. Int J Immunopathol Pharmacol. 2012;25:9–17.

    CAS  PubMed  Google Scholar 

  15. Reiter RJ, Tan D, Korkmaz A, Ma S. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med. 2012;44:564–77.

    CAS  PubMed  Google Scholar 

  16. Gomez-Abellan P, Madrid JA, Ordovas JM, Garaulet M. Chronobiological aspects of obesity and metabolic syndrome. Endocrinol Nutr. 2012;59:50–61.

    PubMed  Google Scholar 

  17. Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci. 2012;69:741–62.

    CAS  PubMed  Google Scholar 

  18. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32:1431–7.

    CAS  Google Scholar 

  19. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815–25.

    PubMed  Google Scholar 

  20. Naukkarinen J, Rissanen A, Kaprio J, Pietiläinen KH. Causes and consequences of obesity: the contribution of recent twin studies. Int J Obes. 2012;36:1017–24.

    CAS  Google Scholar 

  21. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18:139–43.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci. 2009;338:310–8.

    PubMed  Google Scholar 

  23. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008;54:945–55.

    PubMed  Google Scholar 

  24. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal. 2011;15:1911–26.

    CAS  PubMed  Google Scholar 

  25. Ozgen IT, Tascilar ME, Bilir P, Boyraz M, Guncikan MN, Akay C, Dundaroz R. Oxidative stress in obese children and its relation with insulin resistance. J Pediatr Endocrinol Metab. 2012;25:261–6.

    PubMed  Google Scholar 

  26. Ando K, Fujita T. Metabolic syndrome and oxidative stress. Free Radic Biol Med. 2009;47:213–8.

    CAS  PubMed  Google Scholar 

  27. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008;19:491–504.

    CAS  PubMed  Google Scholar 

  28. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Beydoun MA, Shroff MR, Chen X, Beydoun HA, Wang Y, Zonderman AB. Serum antioxidant status is associated with metabolic syndrome among U.S. adults in recent national surveys. J Nutr. 2011;141:903–13.

    CAS  PubMed  Google Scholar 

  30. Beydoun MA, Canas JA, Beydoun HA, Chen X, Shroff MR, Zonderman AB. Serum antioxidant concentrations and metabolic syndrome are associated among U.S. adolescents in recent national surveys. J Nutr. 2012;142:1693–704.

    CAS  PubMed  Google Scholar 

  31. Bahadoran Z, Golzarand M, Mirmiran P, Shiva N, Azizi F. Dietary total antioxidant capacity and the occurrence of metabolic syndrome and its components after a 3-year follow-up in adults: Tehran Lipid and Glucose Study. Nutr Metab. 2012;9:70.

    CAS  Google Scholar 

  32. Tiganis T. Reactive oxygen species and insulin resistance: the good, the bad and the ugly. Trends Pharmacol Sci. 2011;32:82–9.

    CAS  PubMed  Google Scholar 

  33. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med. 2009;15:43–50.

    CAS  PubMed Central  PubMed  Google Scholar 

  34. Korkmaz A, Topal T, Tan DX, Reiter RJ. Role of melatonin in metabolic regulation. Rev Endocr Metab Disord. 2009;10:261–70.

    CAS  PubMed  Google Scholar 

  35. Tan DX, Manchester LC, FuentesBroto L, Paredes SD, Reiter RJ. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev. 2011;12:167–88.

    CAS  PubMed  Google Scholar 

  36. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101–10.

    CAS  PubMed  Google Scholar 

  37. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351:152–66.

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–11.

    CAS  PubMed  Google Scholar 

  39. Mendes KG, Theodoro H, Rodrigues AD, Olinto MT. Prevalence of metabolic syndrome and its components in the menopausal transition: a systematic review. Cad Saude Publica. 2012;28:1423–37.

    PubMed  Google Scholar 

  40. Reiter RJ. The ageing pineal gland and its physiological consequences. Bioessays. 1992;14:169–75.

    CAS  PubMed  Google Scholar 

  41. Hardeland R. Melatonin in aging and disease – multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012;3:194–225.

    PubMed Central  PubMed  Google Scholar 

  42. Shatilo VB, Bondarenko EV, Antoniuk-Shcheglova IA. Metabolic disorders in elderly patients with hypertension and their correction with melatonin. Adv Gerontol. 2012;25:84–9.

    CAS  PubMed  Google Scholar 

  43. Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61:383–410.

    CAS  PubMed  Google Scholar 

  44. Hardeland R, Fuhrberg B. Ubiquitous melatonin—presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol. 1996;2:25–45.

    CAS  Google Scholar 

  45. Bonnefont-Rousselot D, Collin F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology. 2010;278:55–67.

    CAS  PubMed  Google Scholar 

  46. Barrenetxe J, Delagrange P, Martinez JA. Physiological and metabolic functions of melatonin. J Physiol Biochem. 2004;60:61–72.

    CAS  PubMed  Google Scholar 

  47. Venegas C, Garcia JA, Escames G, Ortiz F, Lopez A, Doerrier C, GarciaCorzo L, Lopez LC, Reiter RJ, AcunaCastroviejo D. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52:217–27.

    CAS  PubMed  Google Scholar 

  48. Cardinali DP, Bernasconi PA, Reynoso R, Toso CF, Scacchi P. Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats. Int J Mol Sci. 2013;14:2502–14.

    CAS  PubMed Central  PubMed  Google Scholar 

  49. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin–a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93:350–84.

    CAS  PubMed  Google Scholar 

  50. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc. 1958;80:2587.

    CAS  Google Scholar 

  51. Hardeland R, Pandi-Perumal SR, Cardinali DP. Melatonin. Int J Biochem Cell Biol. 2006;38:313–6.

    CAS  PubMed  Google Scholar 

  52. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature’s most versatile biological signal? FEBS J. 2006;273:2813–38.

    CAS  PubMed  Google Scholar 

  53. Tan D, Hardeland R, Manchester LC, Korkmaz A, Ma S, RosalesCorral S, Reiter RJ. Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science. J Exp Bot. 2012;63:577–97.

    CAS  PubMed  Google Scholar 

  54. Hardeland R, Madrid JA, Tan DX, Reiter RJ. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res. 2012;52:139–66.

    CAS  PubMed  Google Scholar 

  55. Reiter RJ, Tan DX, Jou MJ, Korkmaz A, Manchester LC, Paredes SD. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro Endocrinol Lett. 2008;29:391–8.

    PubMed  Google Scholar 

  56. Sener G, Sehirli AÖ, Ayanoğlu-Dülger G. Protective effects of melatonin, vitamin E and N-acetylcysteine against acetaminophen toxicity in mice: a comparative study. J Pineal Res. 2003;35:61–8.

    CAS  PubMed  Google Scholar 

  57. Montilla-Lopez P, Munoz-Agueda MC, Feijoo Lopez M, Munoz-Castaneda JR, Bujalance-Arenas I, Tunez-Finana I. Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer’s disease induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol. 2002;451:237–43.

    CAS  PubMed  Google Scholar 

  58. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28–42.

    CAS  PubMed  Google Scholar 

  59. Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H, Reiter RJ. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res. 2007;43:317–20.

    CAS  PubMed  Google Scholar 

  60. Korkmaz A, Rosales-Corral S, Reiter RJ. Gene regulation by melatonin linked to epigenetic phenomena. Gene. 2012;503:1–11.

    CAS  PubMed  Google Scholar 

  61. Sanchez-Hidalgo M, Montavez JMG, Carrascosa Salmoral MP, Gutierrez MCN, Lardone PJ, Lardone PJ, de la Lastra Romero CA. Decreased MT1 and MT2 melatonin receptor expression in extrapineal tissues of the rat during physiological aging. J Pineal Res. 2009;46:29–35.

    CAS  PubMed  Google Scholar 

  62. Stefulj J, Hörtner M, Ghosh M, Schauenstein K, Rinner I, Wölfler A, Semmler J, Liebmann PM. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30:243–7.

    CAS  PubMed  Google Scholar 

  63. Sanchez-Hidalgo M, de la Lastra CA, Carrascosa-Salmoral MP, Naranjo MC, Gomez-Corvera A, Caballero B, Guerrero JM. Age-related changes in melatonin synthesis in rat extrapineal tissues. Exp Gerontol. 2009;44:328–34.

    CAS  PubMed  Google Scholar 

  64. Hernandez C, Abreu J, Abreu P, Castro A, Jimenez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J. 2007;30:496–500.

    CAS  PubMed  Google Scholar 

  65. Sae-Teaw M, Johns J, Johns NP, Subongkot S. Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers. J Pineal Res. 2013;55:58–64.

    CAS  PubMed  Google Scholar 

  66. Johns NP, Johns J, Porasuphatana S, Plaimee P, Sae-Teaw M. Dietary intake of melatonin from tropical fruit altered urinary excretion of 6-sulfatoxymelatonin in healthy volunteers. J Agric Food Chem. 2013;61:913–9.

    CAS  PubMed  Google Scholar 

  67. Iriti M, Varoni EM, Vitalini S. Melatonin in traditional Mediterranean diets. J Pineal Res. 2010;49:101–5.

    CAS  PubMed  Google Scholar 

  68. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011;57:1299–313.

    CAS  PubMed  Google Scholar 

  69. Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res. 2011;50:374–80.

    CAS  PubMed  Google Scholar 

  70. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, Kaski JC, Reiter RJ. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res. 2010;49:14–22.

    CAS  PubMed  Google Scholar 

  71. Takeda N, Maemura K. Circadian clock and cardiovascular disease. J Cardiol. 2011;57:249–56.

    PubMed  Google Scholar 

  72. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia MJ, Sanchez J, Marrero F, de Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res. 2002;33:248–52.

    CAS  PubMed  Google Scholar 

  73. Muller JE, Ludmer PL, Willich SN, Tofler GH, Aylmer G, Klangos I, Stone PH. Circadian variation in the frequency of sudden cardiac death. Circulation. 1987;75:131–8.

    CAS  PubMed  Google Scholar 

  74. Siegel D, Black DM, Seeley DG, Hulley SB. Circadian variation in ventricular arrhythmias in hypertensive men. Am J Cardiol. 1992;69:344–7.

    CAS  PubMed  Google Scholar 

  75. Altun A, Yaprak M, Aktoz M, Vardar A, Betul UA, Ozbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett. 2002;327:143–5.

    CAS  PubMed  Google Scholar 

  76. Schepelmann M, Molcan L, Uhrova H, Zeman M, Ellinger I. The presence and localization of melatonin receptors in the rat aorta. Cell Mol Neurobiol. 2011;31:1257–65.

    CAS  PubMed  Google Scholar 

  77. Ekmekcioglu C, Thalhammer T, Humpeler S, Mehrabi MR, Glogar HD, Holzenbein T, Markovic O, Leibetseder VJ, Strauss-Blasche G, Marktl W. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res. 2003;35:40–4.

    CAS  PubMed  Google Scholar 

  78. Peliciari-Garcia RA, Zanquetta MM, Andrade-Silva J, Gomes DA, Barreto-Chaves ML, Cipolla-Neto J. Expression of circadian clock and melatonin receptors within cultured rat cardiomyocytes. Chronobiol Int. 2011;28:21–30.

    CAS  PubMed  Google Scholar 

  79. Scheer FA, Kalsbeek A, Buijs RM. Cardiovascular control by the suprachiasmatic nucleus: neural and neuroendocrine mechanisms in human and rat. Biol Chem. 2003;384:697–709.

    CAS  PubMed  Google Scholar 

  80. Durgan DJ, Young ME. The cardiomyocyte circadian clock. Circ Res. 2010;106:647–58.

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Reilly DF, Westgate EJ, FitzGerald GA. Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol. 2007;27:1694–705.

    CAS  PubMed  Google Scholar 

  82. Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res. 2011;50:171–82.

    CAS  PubMed  Google Scholar 

  83. Bojkova B, Orendas P, Friedmanova L, Kassayova M, Datelinka I, Ahlersova E, Ahlers I. Prolonged melatonin administration in 6-month-old Sprague–Dawley rats: metabolic alterations. Acta Physiol Hung. 2008;95:65–76.

    CAS  PubMed  Google Scholar 

  84. Kassayova M, Markova M, Bojkova B, Adamekova E, Kubatka P, Ahlersova E, Ahlers I. Influence of long-term melatonin administration on basic physiological and metabolic variables of young Wistar:Han rats. Biologia. 2006;61:313–20.

    CAS  Google Scholar 

  85. Patel V, Upaganlawar A, Zalawadia R, Balaraman R. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: a biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol. 2010;644:160–8.

    CAS  PubMed  Google Scholar 

  86. Kitajima T, Kanbayashi T, Saitoh Y, Ogawa Y, Sugiyama T, Kaneko Y, Sasaki Y, Aizawa R, Shimisu T. The effects of oral melatonin on the autonomic function in healthy subjects. Psychiatry Clin Neurosci. 2001;55:299–300.

    CAS  PubMed  Google Scholar 

  87. Mizrak B, Parlakpinar H, Acet A, Turkoz Y. Effects of pinealectomy and exogenous melatonin on rat hearts. Acta Histochem. 2004;106:29–36.

    CAS  PubMed  Google Scholar 

  88. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet. 1995;345:1408.

    CAS  PubMed  Google Scholar 

  89. SamimiFard S, AbreuGonzalez P, DominguezRodriguez A, JimenezSosa A. A case–control study of melatonin receptor type 1A polymorphism and acute myocardial infarction in a Spanish population. J Pineal Res. 2011;51:400–4.

    CAS  Google Scholar 

  90. Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, Reiter RJ. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res. 2012;53:319–23.

    CAS  PubMed  Google Scholar 

  91. Garakyaraghi M, Siavash M, Alizadeh MK. Effects of melatonin on left ventricular ejection fraction and functional class of heart failure patients: a randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2012;17:S13–6.

    Google Scholar 

  92. Opie LH. Heart physiology from cell to circulation. Philadelphia: Williams & Wilkens; 2004.

    Google Scholar 

  93. Kaneko S, Okumura K, Numaguchi Y, Matsui H, Murase K, Mokuno S, Morishima I, Hira K, Toki Y, Ito T, Hayakawa T. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury. Life Sci. 2000;67:101–12.

    CAS  PubMed  Google Scholar 

  94. Lagneux C, Joyeux M, Demenge P, Ribuot C, Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci. 2000;66:503–9.

    CAS  PubMed  Google Scholar 

  95. Szarszoi O, Asemu G, Vanecek J, Ost’adal B, Kolar F. Effects of melatonin on ischemia and reperfusion injury of the rat heart. Cardiovasc Drugs Ther. 2001;15:251–7.

    CAS  PubMed  Google Scholar 

  96. Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ, El-Sokkary GH. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res. 1998;25:184–91.

    CAS  PubMed  Google Scholar 

  97. Salie R, Harper I, Cillie C, Genade S, Huisamen B, Moolman J, Lochner A. Melatonin protects against ischaemic-reperfusion myocardial damage. J Mol Cell Cardiol. 2001;33:343–57.

    CAS  PubMed  Google Scholar 

  98. Lee YM, Chen HR, Hsiao G, Sheu JR, Wang JJ, Yen MH. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res. 2002;33:72–80.

    CAS  PubMed  Google Scholar 

  99. Sahna E, Acet A, Ozer MK, Olmez E. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res. 2002;33:234–8.

    CAS  PubMed  Google Scholar 

  100. Sahna E, Parlakpinar H, Turkoz Y, Acet A. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. Physiol Res. 2005;54:491–5.

    CAS  PubMed  Google Scholar 

  101. Sahna E, Olmez E, Acet A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? J Pineal Res. 2002;32:194–8.

    CAS  PubMed  Google Scholar 

  102. Lochner A, Genade S, Davids A, Ytrehus K, Moolman JA. Short- and long-term effects of melatonin on myocardial post-ischemic recovery. J Pineal Res. 2006;40:56–63.

    CAS  PubMed  Google Scholar 

  103. Lochner A, Huisamen B, Nduhirabandi F. Cardioprotective effect of melatonin against ischaemia/reperfusion damage. Front Biosci (Elite Ed). 2013;5:305–15.

    Google Scholar 

  104. Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Beneficial effects of melatonin in cardiovascular disease. Ann Med. 2010;42:276–85.

    CAS  PubMed  Google Scholar 

  105. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol. 2009;7:367–73.

    CAS  PubMed  Google Scholar 

  106. Genade S, Genis A, Ytrehus K, Huisamen B, Lochner A. Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions. J Pineal Res. 2008;45:449–58.

    CAS  PubMed  Google Scholar 

  107. Sallinen P, Manttari S, Leskinen H, Ilves M, Vakkuri O, Ruskoaho H, Saarela S. The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. J Pineal Res. 2007;42:254–60.

    CAS  PubMed  Google Scholar 

  108. Petrosillo G, Colantuono G, Moro N, Ruggiero FM, Tiravanti E, Di Venosa N, Fiore T, Paradies G. Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Physiol Heart Circ Physiol. 2009;297:H1487–93.

    CAS  PubMed  Google Scholar 

  109. Petrosillo G, Moro N, Paradies V, Ruggiero FM, Paradies G. Increased susceptibility to Ca(2+)-induced permeability transition and to cytochrome c release in rat heart mitochondria with aging: effect of melatonin. J Pineal Res. 2010;48:340–6.

    CAS  PubMed  Google Scholar 

  110. Ghosh G, De K, Maity S, Bandyopadhyay D, Bhattacharya S, Reiter RJ, Bandyopadhyay A. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J Pineal Res. 2007;42:71–82.

    CAS  PubMed  Google Scholar 

  111. Mukherjee R, Banerjee S, Joshi N, Singh PK, Baxi D, Ramachandran AV. A combination of melatonin and alpha lipoic acid has greater cardioprotective effect than either of them singly against cadmium-induced oxidative damage. Cardiovasc Toxicol. 2011;11:78–88.

    CAS  PubMed  Google Scholar 

  112. Reiter RJ, Manchester LC, FuentesBroto L, Tan D. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens. 2010;28:S7–12.

    CAS  PubMed  Google Scholar 

  113. Chen Z, Chua CC, Gao J, Hamdy RC, Chua BH. Protective effect of melatonin on myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284:H1618–24.

    CAS  PubMed  Google Scholar 

  114. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. American Heart Association, Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918.

    PubMed  Google Scholar 

  115. Qin X, Zhang Y, Cai Y, He M, Sun L, Fu J, Li J, Wang B, Xing H, Tang G, Wang X, Xu X, Xu X, Huo Y. Prevalence of obesity, abdominal obesity and associated factors in hypertensive adults aged 45–75 years. Clin Nutr. 2013;32(3):361–7.

    PubMed  Google Scholar 

  116. Cook JS, Sauder CL, Ray CA. Melatonin differentially affects vascular blood flow in humans. Am J Physiol Heart Circ Physiol. 2011;300:H670–4.

    CAS  PubMed  Google Scholar 

  117. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577–84.

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Rechcinski T, Trzos E, Wierzbowska-Drabik K, Krzeminska-Pakula M, Kurpesa M. Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens Res. 2010;33:56–61.

    CAS  PubMed  Google Scholar 

  119. Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res. 2007;56:671–84.

    CAS  PubMed  Google Scholar 

  120. Karppanen H, Lahovaara S, Mannisto P, Vapaatalo H. Plasma renin activity and in vitro synthesis of aldosterone by the adrenal glands of rats with spontaneous, renal, or pinealectomy-induced hypertension. Acta Physiol Scand. 1975;94:184–8.

    CAS  PubMed  Google Scholar 

  121. Zanoboni A, Zanoboni-Muciaccia W. Experimental hypertension in pinealectomized rats. Life Sci. 1967;6:2327–31.

    CAS  PubMed  Google Scholar 

  122. Holmes SW, Sugden D. Proceedings: the effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol. 1976;56:360P–1.

    CAS  PubMed  Google Scholar 

  123. Katsi V, Karagiorgi I, Makris T, Papavasileiou M, Androulakis AE, Tsioufis C, Tousoulis D, Stefanadis C, Kallikazaros IE. The role of melatonin in hypertension: a brief review. Cardiovasc Endocrinol. 2012;1:13–8.

    CAS  Google Scholar 

  124. Lusardi P, Preti P, Savino S, Piazza E, Zoppi A, Fogari R. Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit. 1997;2:99–103.

    PubMed  Google Scholar 

  125. Yildiz M, Sahin B, Sahin A. Acute effects of oral melatonin administration on arterial distensibility, as determined by carotid-femoral pulse wave velocity, in healthy young men. Exp Clin Cardiol. 2006;11:311–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  126. Yildiz M, Akdemir O. Assessment of the effects of physiological release of melatonin on arterial distensibility and blood pressure. Cardiol Young. 2009;19:198–203.

    PubMed  Google Scholar 

  127. Forman JP, Curhan GC, Schernhammer ES. Urinary melatonin and risk of incident hypertension among young women. J Hypertens. 2010;28:446–51.

    CAS  PubMed Central  PubMed  Google Scholar 

  128. Zeman M, Dulková K, Bada V, Herichová I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci. 2005;76:1795–803.

    CAS  PubMed  Google Scholar 

  129. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2003;12:19–24.

    PubMed  Google Scholar 

  130. Simko F. Chronobiology of blood pressure: emerging implications of melatonin. Eur J Clin Invest. 2012;42:1252–4.

    PubMed  Google Scholar 

  131. Leibowitz A, Peleg E, Sharabi Y, Shabtai Z, Shamiss A, Grossman E. The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. Am J Hypertens. 2008;21:348–51.

    CAS  PubMed  Google Scholar 

  132. Kozirog M, Poliwczak AR, Duchnowicz P, KoterMichalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50:261–6.

    CAS  PubMed  Google Scholar 

  133. Pechanova O, Parohova J, Vrankova S, Barta A, Kovacsova M, Janega P. 604 Effect of melatonin on blood pressure and fibrosis enlargement in the heart and aorta in experimental metabolic syndrome. J Hypertens. 2012;30:e177.

    Google Scholar 

  134. Witt-Enderby PA, Dubocovich ML. Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells. Mol Pharmacol. 1996;50:166–74.

    CAS  PubMed  Google Scholar 

  135. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci. 1995;16:50–6.

    CAS  PubMed  Google Scholar 

  136. Anwar MM, Meki AR, Rahma HH. Inhibitory effects of melatonin on vascular reactivity: possible role of vasoactive mediators. Comp Biochem Physiol C Toxicol Pharmacol. 2001;130:357–67.

    CAS  PubMed  Google Scholar 

  137. Grossini E, Molinari C, Uberti F, Mary DA, Vacca G, Caimmi PP. Intracoronary melatonin increases coronary blood flow and cardiac function through beta-adrenoreceptors, MT1/MT2 receptors, and nitric oxide in anesthetized pigs. J Pineal Res. 2011;51:246–57.

    CAS  PubMed  Google Scholar 

  138. Pechanova O, Zicha J, Paulis L, Zenebe W, Dobesova Z, Kojsova S, Jendekova L, Sladkova M, Dovinova I, Simko F, Kunes J. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol. 2007;561:129–36.

    CAS  PubMed  Google Scholar 

  139. Ersahin M, Sehirli O, Toklu HZ, Suleymanoglu S, EmekliAlturfan E, Yarat A, Tatldede E, Yegen BC, Sener G. Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res. 2009;47:97–106.

    CAS  PubMed  Google Scholar 

  140. Reiter RJ, Tan D, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens. 2009;27:S17–20.

    CAS  Google Scholar 

  141. Campos LA, Cipolla-Neto J, Amaral FG, Michelini LC, Bader M, Baltatu OC. The Angiotensin-melatonin axis. Int J Hypertens. 2013;2013:521783.

    PubMed Central  PubMed  Google Scholar 

  142. van der Helm-van Mil Annette HM, van Someren EJW, van den Boom R, van Buchem MA, de Craen AJM, Blauw GJ. No influence of melatonin on cerebral blood flow in humans. J Clin Endocrinol Metab. 2003;88:5989–94.

    PubMed  Google Scholar 

  143. Bang J, Park YS, Jeong S, Song J, Kim Y, Hwang G. Melatonin does not attenuate dynamic cardiovascular and cerebrovascular reflex responses to acute hypotension in healthy men. Korean J Anesthesiol. 2012;63:245–52.

    CAS  PubMed Central  PubMed  Google Scholar 

  144. Tunstall RR, Shukla P, Grazul-Bilska A, Sun C, O’Rourke ST. MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries. J Pharmacol Exp Ther. 2011;336:127–33.

    CAS  PubMed  Google Scholar 

  145. Thakor AS, Herrera EA, SeronFerre M, Giussani DA. Melatonin and vitamin C increase umbilical blood flow via nitric oxide-dependent mechanisms. J Pineal Res. 2010;49:399–406.

    CAS  PubMed  Google Scholar 

  146. Bray MS, Young ME. Chronobiological effects on obesity. Curr Obes Rep. 2012;1:9–15.

    Google Scholar 

  147. Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, Cannavan FP, Moreno Jr H. Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol. 2011;10:24.

    CAS  PubMed Central  PubMed  Google Scholar 

  148. Lund J, Arendt J, Hampton SM, English J, Morgan LM. Postprandial hormone and metabolic responses amongst shift workers in Antarctica. J Endocrinol. 2001;171:557–64.

    CAS  PubMed  Google Scholar 

  149. Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, Spessert R, Muhlbauer E. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40:135–43.

    CAS  PubMed  Google Scholar 

  150. Cano P, Jimenez-Ortega V, Larrad A, Reyes Toso CF, Cardinali DP, Esquifino AI. Effect of a high-fat diet on 24-h pattern of circulating levels of prolactin, luteinizing hormone, testosterone, corticosterone, thyroid-stimulating hormone and glucose, and pineal melatonin content, in rats. Endocrine. 2008;33:118–25.

    CAS  PubMed  Google Scholar 

  151. Cardinali DP, Pagano ES, Scacchi Bernasconi PA, Reynoso R, Scacchi P. Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. Neuro Endocrinol Lett. 2011;32:588–606.

    CAS  PubMed  Google Scholar 

  152. She M, Deng X, Guo Z, Laudon M, Hu Z, Liao D, Hu X, Luo Y, Shen Q, Su Z, Yin W. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol Res. 2009;59:248–53.

    CAS  PubMed  Google Scholar 

  153. Oxenkrug GF, Summergrad P. Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats. Ann N Y Acad Sci. 2010;1199:114–20.

    CAS  PubMed  Google Scholar 

  154. Bartness TJ, Wade GN. Body weight, food intake and energy regulation in exercising and melatonin-treated siberian hamsters. Physiol Behav. 1985;35:805–8.

    CAS  PubMed  Google Scholar 

  155. Arendt J. Melatonin and human rhythms. Chronobiol Int. 2006;23:21–37.

    CAS  PubMed  Google Scholar 

  156. Bartness TJ, Demas GE, Song CK. Seasonal changes in adiposity: the roles of the photoperiod, melatonin and other hormones, and sympathetic nervous system. Exp Biol Med (Maywood). 2002;227:363–76.

    CAS  Google Scholar 

  157. Larkin LM, Moore BJ, Stern JS, Horwitz BA. Effect of photoperiod on body weight and food intake of obese and lean Zucker rats. Life Sci. 1991;49:735–45.

    CAS  PubMed  Google Scholar 

  158. Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P, Casteilla L, Penicaud L. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology. 2003;144:5347–52.

    CAS  PubMed  Google Scholar 

  159. Kurcer Z, Sahna E, Olmez E. Vascular reactivity to various vasoconstrictor agents and endothelium-dependent relaxations of rat thoracic aorta in the long-term period of pinealectomy. J Pharmacol Sci. 2006;101:329–34.

    CAS  PubMed  Google Scholar 

  160. Bojkova B, Markova M, Ahlersova E, Ahlers I, Adamekova E, Kubatka P, Kassayova M. Metabolic effects of prolonged melatonin administration and short-term fasting in laboratory rats. Acta Vet Brno. 2006;75:21–32.

    CAS  Google Scholar 

  161. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology. 1999;140:1009–12.

    CAS  PubMed  Google Scholar 

  162. Rasmussen DD, Mitton DR, Larsen SA, Yellon SM. Aging-dependent changes in the effect of daily melatonin supplementation on rat metabolic and behavioral responses. J Pineal Res. 2001;31:89–94.

    CAS  PubMed  Google Scholar 

  163. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, Rasmussen DD. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology. 2000;141:487–97.

    CAS  PubMed  Google Scholar 

  164. Puchalski SS, Green JN, Rasmussen DD. Melatonin effects on metabolism independent of gonad function. Endocrine. 2003;21:169–73.

    CAS  PubMed  Google Scholar 

  165. Agil A, Navarro-Alarcon M, Ruiz R, Abuhamadah S, El-Mir MY, Vazquez GF. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J Pineal Res. 2011;50:207–12.

    CAS  PubMed  Google Scholar 

  166. Ríos-Lugo MJ, Cano P, Jiménez-Ortega V, Fernández-Mateos MP, Scacchi PA, Cardinali DP, Esquifino AI. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat? Fed rats. J Pineal Res. 2010;49:342–8.

    PubMed  Google Scholar 

  167. Hussein MR, Ahmed OG, Hassan AF, Ahmed MA. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol. 2007;88:19–29.

    CAS  PubMed Central  PubMed  Google Scholar 

  168. Shieh JM, Wu HT, Cheng KC, Cheng JT. Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK3beta pathway in hepatic cells. J Pineal Res. 2009;47:339–44.

    CAS  PubMed  Google Scholar 

  169. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf). 2012;205:209–23.

    CAS  Google Scholar 

  170. Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernandez-Vazquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res. 2012;52:203–10.

    CAS  PubMed  Google Scholar 

  171. Puchalski SS, Green JN, Rasmussen DD. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. Endocrine. 2003;21:163–7.

    CAS  PubMed  Google Scholar 

  172. Sanchez-Mateos S, Alonso-Gonzalez C, Gonzalez A, Martinez-Campa CM, Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. Maturitas. 2007;58:91–101.

    CAS  PubMed  Google Scholar 

  173. Baxi D, Singh PK, Vachhrajani K, Ramachandran AV. Melatonin supplementation therapy as a potent alternative to ERT in ovariectomized rats. Climacteric. 2012;15:382–92.

    CAS  PubMed  Google Scholar 

  174. Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology. 2007;32:284–8.

    CAS  PubMed  Google Scholar 

  175. Hoyos M, Guerrero JM, Perez-Cano R, Olivan J, Fabiani F, Garcia-Perganeda A, Osuna C. Serum cholesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats. J Pineal Res. 2000;28:150–5.

    CAS  PubMed  Google Scholar 

  176. Hussain SA. Effect of melatonin on cholesterol absorption in rats. J Pineal Res. 2007;42:267–71.

    CAS  PubMed  Google Scholar 

  177. Zhang K, Lv Z, Jia X, Huang D. Melatonin prevents testicular damage in hyperlipidaemic mice. Andrologia. 2012;44:230–6.

    CAS  PubMed  Google Scholar 

  178. Kitagawa A, Ohta Y, Ohashi K. Melatonin improves metabolic syndrome induced by high fructose intake in rats. J Pineal Res. 2012;52:403–13.

    CAS  PubMed  Google Scholar 

  179. D’Archivio M, Annuzzi G, Vari R, Filesi C, Giacco R, Scazzocchio B, Santangelo C, Giovannini C, Rivellese AA, Masella R. Predominant role of obesity/insulin resistance in oxidative stress development. Eur J Clin Invest. 2012;42:70–78.

    Google Scholar 

  180. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress In humans. Int J Obes (Lond). 2006;30:400–18.

    CAS  Google Scholar 

  181. Agil A, Reiter RJ, Jimenez-Aranda A, Iban-Arias R, Navarro-Alarcon M, Marchal JA, Adem A, Fernandez-Vazquez G. Melatonin ameliorates low-grade inflammation and oxidative stress in young zucker diabetic fatty rats. J Pineal Res. 2013;54:381–88.

    Google Scholar 

  182. de Rooij SR, Nijpels G, Nilsson PM, Nolan JJ, Gabriel R, Bobbioni-Harsch E, Mingrone G, Dekker JM, Relationship Between Insulin Sensitivity and Cardiovascular Disease (RISC) Investigators. Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profile. Diabetes Care. 2009;32:1295–301.

    PubMed  Google Scholar 

  183. Nishida S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine. 2005;27:131–6.

    CAS  PubMed  Google Scholar 

  184. Pita ML, Hoyos M, Martin-Lacave I, Osuna C, Fernández-Santos JM, Guerrero JM. Long-term melatonin administration increases polyunsaturated fatty acid percentage in plasma lipids of hypercholesterolemic rats. J Pineal Res. 2002;32:179–86.

    CAS  PubMed  Google Scholar 

  185. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res. 2009;83:247–61.

    CAS  PubMed  Google Scholar 

  186. Kloner RA, Schwartz LL. State of the science of cardioprotection: challenges and opportunities – proceedings of the 2010 NHLBI Workshop on Cardioprotection. J Cardiovasc Pharmacol Ther. 2011;16:223–32.

    CAS  PubMed  Google Scholar 

  187. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J. 2009;73:1171–7.

    PubMed  Google Scholar 

  188. Shafii M, MacMillan DR, Key MP, Kaufman N, Nahinsky ID. Case study: melatonin in severe obesity. J Am Acad Child Adolesc Psychiatry. 1997;36:412–6.

    CAS  PubMed  Google Scholar 

  189. Tutuncu NB, Batur MK, Yildirir A, Tutuncu T, Deger A, Koray Z, Erbas B, Kabakci G, Aksoyek S, Erbas T. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res. 2005;39:43–9.

    CAS  PubMed  Google Scholar 

  190. Hikichi T, Tateda N, Miura T. Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy. Clin Ophthalmol. 2011;5:655–60.

    PubMed Central  PubMed  Google Scholar 

  191. Cardinali DP, Cano P, Jimenez-Ortega V, Esquifino AI. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology. 2011;93:133–42.

    CAS  PubMed  Google Scholar 

  192. Lipton J, Megerian JT, Kothare SV, Cho YJ, Shanahan T, Chart H, Ferber R, Adler-Golden L, Cohen LE, Czeisler CA, Pomeroy SL. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology. 2009;73:323–5.

    CAS  PubMed  Google Scholar 

  193. Mantele S, Otway DT, Middleton B, Bretschneider S, Wright J, Robertson MD, Skene DJ, Johnston JD. Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men. PLoS One. 2012;7:e37123.

    CAS  PubMed Central  PubMed  Google Scholar 

  194. Robeva R, Kirilov G, Tomova A, Kumanov P. Melatonin-insulin interactions in patients with metabolic syndrome. J Pineal Res. 2008;44:52–6.

    CAS  PubMed  Google Scholar 

  195. Robeva R, Kirilov G, Tomova A, Kumanov P. Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome. Andrologia. 2006;38:216–20.

    CAS  PubMed  Google Scholar 

  196. Lee J, Yoon J, Lee JA, Lee SY, Shin CH, Yang SW. Urinary 6-sulfatoxymelatonin level in girls and its relationship with obesity. Korean J Pediatr. 2012;55:344–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  197. Rojdmark S, Berg A, Rossner S, Wetterberg L. Nocturnal melatonin secretion in thyroid disease and in obesity. Clin Endocrinol (Oxf). 1991;35:61–5.

    CAS  Google Scholar 

  198. Ozguner F, Koyu A, Cesur G. Active smoking causes oxidative stress and decreases blood melatonin levels. Toxicol Ind Health. 2005;21:21–6.

    CAS  PubMed  Google Scholar 

  199. Muller HL, Handwerker G, Gebhardt U, Faldum A, Emser A, Kolb R, Sorensen N. Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. Cancer Causes Control. 2006;17:583–9.

    PubMed  Google Scholar 

  200. LeGouic S, Delagrange P, Atgie C, Nibbelink M, Hanoun N, Casteilla L, Renard P, Lesieur D, GuardiolaLemaitre B, Ambid L. Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. Int J Obes. 1996;20:661–7.

    CAS  Google Scholar 

  201. Muhlbauer E, Gross E, Labucay K, Wolgast S, Peschke E. Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol. 2009;606:61–71.

    PubMed  Google Scholar 

  202. Brydon L, Petit L, Delagrange P, Strosberg AD, Jockers R. Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology. 2001;142:4264–71.

    CAS  PubMed  Google Scholar 

  203. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, Loos RJ, Manning AK, Jackson AU, Aulchenko Y, Potter SC, Erdos MR, Sanna S, Hottenga JJ, Wheeler E, Kaakinen M, Lyssenko V, Chen WM, Ahmadi K, Beckmann JS, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41:77–81.

    CAS  PubMed Central  PubMed  Google Scholar 

  204. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Rocheleau G, Durand E, De Graeve F, Chevre JC, Borch-Johnsen K, Hartikainen AL, Ruokonen A, Tichet J, Marre M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89–94.

    CAS  PubMed  Google Scholar 

  205. Ling Y, Li X, Gu Q, Chen H, Lu D, Gao X. A common polymorphism rs3781637 in MTNR1B is associated with type 2 diabetes and lipids levels in Han Chinese individuals. Cardiovasc Diabetol. 2011;10:27.

    CAS  PubMed Central  PubMed  Google Scholar 

  206. Tabara Y, Osawa H, Kawamoto R, Onuma H, Shimizu I, Makino H, Kohara K, Miki T. Genotype risk score of common susceptible variants for prediction of type 2 diabetes mellitus in Japanese: the Shimanami Health Promoting Program (J-SHIPP study). Development of type 2 diabetes mellitus and genotype risk score. Metabolism. 2011;60:1634–40.

    CAS  PubMed  Google Scholar 

  207. Song CK, Bartness TJ. CNS sympathetic outflow neurons to white fat that express MEL receptors may mediate seasonal adiposity. Am J Physiol Regul Integr Comp Physiol. 2001;281:R666–72.

    CAS  PubMed  Google Scholar 

  208. Alonso-Vale MI, Peres SB, Vernochet C, Farmer SR, Lima FB. Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity. J Pineal Res. 2009;47:221–7.

    CAS  PubMed  Google Scholar 

  209. Sanchez-Hidalgo M, Lu Z, Tan DX, Maldonado MD, Reiter RJ, Gregerman RI. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol. 2007;292:R2208–15.

    CAS  PubMed  Google Scholar 

  210. Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, Scherrer U, Duplain H. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150:5311–7.

    CAS  PubMed  Google Scholar 

  211. Townsend K, Tseng Y. Brown adipose tissue: recent insights into development, metabolic function and therapeutic potential. Adipocyte. 2012;1:13–24.

    PubMed Central  PubMed  Google Scholar 

  212. Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin as adiposity signals. Recent Prog Horm Res. 2004;59:267–85.

    CAS  PubMed  Google Scholar 

  213. Scarpace PJ, Zhang Y. Leptin resistance: a predisposing factor for diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2009;296:R493–500.

    CAS  PubMed  Google Scholar 

  214. Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O. Leptin beyond body weight regulation–current concepts concerning its role in immune function and inflammation. Cell Immunol. 2008;252:139–45.

    CAS  PubMed  Google Scholar 

  215. Baydas G, Gursu F, Canpolat S, Konar V, Yasar A, Canatan H, Kelestimur H. Effects of pinealectomy on the circadian release pattern of leptin in male rat. Neuro Endocrinol Lett. 2001;22:449–52.

    CAS  PubMed  Google Scholar 

  216. Canpolat S, Sandal S, Yilmaz B, Yasar A, Kutlu S, Baydas G, Kelestimur H. Effects of pinealectomy and exogenous melatonin on serum leptin levels in male rat. Eur J Pharmacol. 2001;428:145–8.

    CAS  PubMed  Google Scholar 

  217. Morrison CD, Huypens P, Stewart LK, Gettys TW. Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity. Biochim Biophys Acta. 2009;1792:409–16.

    CAS  PubMed Central  PubMed  Google Scholar 

  218. Baltaci AK, Mogulkoc R. Pinealectomy and melatonin administration in rats: their effects on plasma leptin levels and relationship with zinc. Acta Biol Hung. 2007;58:335–43.

    CAS  PubMed  Google Scholar 

  219. Song YM, Chen MD. Effects of melatonin administration on plasma leptin concentration and adipose tissue leptin secretion in mice. Acta Biol Hung. 2009;60:399–407.

    PubMed  Google Scholar 

  220. Buff PR, Morrison CD, Ganjam VK, Keisler DH. Effects of short-term feed deprivation and melatonin implants on circadian patterns of leptin in the horse. J Anim Sci. 2005;83:1023–32.

    CAS  PubMed  Google Scholar 

  221. Cagnacci A, Malmusi S, Zanni A, Arangino S, Cagnacci P, Volpe A. Acute modifications in the levels of daytime melatonin do not influence leptin in postmenopausal women. J Pineal Res. 2002;33:57–60.

    CAS  PubMed  Google Scholar 

  222. Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem. 1999;274:30059–65.

    CAS  PubMed  Google Scholar 

  223. Emilsson V, Arch JR, de Groot RP, Lister CA, Cawthorne MA. Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett. 1999;455:170–4.

    CAS  PubMed  Google Scholar 

  224. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–56.

    CAS  PubMed  Google Scholar 

  225. Carvalheira JB, Siloto RM, Ignacchitti I, Brenelli SL, Carvalho CR, Leite A, Velloso LA, Gontijo JA, Saad MJ. Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. FEBS Lett. 2001;500:119–24.

    CAS  PubMed  Google Scholar 

  226. Anhe GF, Caperuto LC, Pereira-Da-Silva M, Souza LC, Hirata AE, Velloso LA, Cipolla-Neto J, Carvalho CR. In vivo activation of insulin receptor tyrosine kinase by melatonin in the rat hypothalamus. J Neurochem. 2004;90:559–66.

    CAS  PubMed  Google Scholar 

  227. Picinato MC, Hirata AE, Cipolla-Neto J, Curi R, Carvalho CR, Anhe GF, Carpinelli AR. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res. 2008;44:88–94.

    CAS  PubMed  Google Scholar 

  228. Benito M. Tissue specificity on insulin action and resistance: past to recent mechanisms. Acta Physiol (Oxf). 2011;201:297–312.

    CAS  Google Scholar 

  229. Tesauro M, Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol (Oxf). 2011;203:279–86.

    CAS  Google Scholar 

  230. Utzschneider KM, Van de Lagemaat A, Faulenbach MV, Goedecke JH, Carr DB, Boyko EJ, Fujimoto WY, Kahn SE. Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes. Obesity (Silver Spring). 2010;18:1781–7.

    CAS  Google Scholar 

  231. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism. 2004;53:495–9.

    CAS  PubMed  Google Scholar 

  232. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19:81–7.

    CAS  PubMed  Google Scholar 

  233. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res. 2008;44:26–40.

    CAS  PubMed  Google Scholar 

  234. Peschke E, Muhlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab. 2010;24:829–41.

    CAS  PubMed  Google Scholar 

  235. Zanquetta MM, Seraphim PM, Sumida DH, Cipolla-Neto J, Machado UF. Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane. J Pineal Res. 2003;35:141–8.

    CAS  PubMed  Google Scholar 

  236. Lima FB, Machado UF, Bartol I, Seraphim PM, Sumida DH, Moraes SM, Hell NS, Okamoto MM, Saad MJ, Carvalho CR, Cipolla-Neto J. Pinealectomy causes glucose intolerance and decreases adipose cell responsiveness to insulin in rats. Am J Physiol. 1998;275:E934–41.

    CAS  PubMed  Google Scholar 

  237. Nishida S, Sato R, Murai I, Nakagawa S. Effect of pinealectomy on plasma levels of insulin and leptin and on hepatic lipids in type 2 diabetic rats. J Pineal Res. 2003;35:251–6.

    CAS  PubMed  Google Scholar 

  238. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T, Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65–85.

    PubMed  Google Scholar 

  239. Frese T, Bach AG, Muhlbauer E, Ponicke K, Bromme HJ, Welp A, Peschke E. Pineal melatonin synthesis is decreased in type 2 diabetic Goto-Kakizaki rats. Life Sci. 2009;85:526–33.

    CAS  PubMed  Google Scholar 

  240. Peschke E, Schucht H, Muhlbauer E. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats. J Pineal Res. 2010;49:373–81.

    CAS  PubMed  Google Scholar 

  241. Nishida S, Segawa T, Murai I, Nakagawa S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res. 2002;32:26–33.

    CAS  PubMed  Google Scholar 

  242. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012;165:574–90.

    CAS  PubMed  Google Scholar 

  243. Ha E, Yim SV, Chung JH, Yoon KS, Kang I, Cho YH, Baik HH. Melatonin stimulates glucose transport via insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway in C2C12 murine skeletal muscle cells. J Pineal Res. 2006;41:67–72.

    CAS  PubMed  Google Scholar 

  244. Banerjee A, Udin S, Krishna A. Regulation of leptin synthesis in white adipose tissue of the female fruit bat, Cynopterus sphinx: role of melatonin with or without insulin. Exp Physiol. 2011;96:216–25.

    CAS  PubMed  Google Scholar 

  245. Contreras-Alcantara S, Baba K, Tosini G. Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity (Silver Spring). 2010;18(9):1861–3.

    CAS  Google Scholar 

  246. Kan MY, Zhou DZ, Zhang D, Zhang Z, Chen Z, Yang YF, Guo XZ, Xu H, He L, Liu Y. Two susceptible diabetogenic variants near/in MTNR1B are associated with fasting plasma glucose in a Han Chinese cohort. Diabet Med. 2010;27:598–602.

    CAS  PubMed  Google Scholar 

  247. Tam CH, Ho JS, Wang Y, Lee HM, Lam VK, Germer S, Martin M, So WY, Ma RC, Chan JC, Ng MC. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta cell function in Chinese subjects. PLoS One. 2010;5:e11428.

    PubMed Central  PubMed  Google Scholar 

  248. Peschke E, Fauteck JD, Musshoff U, Schmidt F, Beckmann A, Peschke D. Evidence for a melatonin receptor within pancreatic islets of neonate rats: functional, autoradiographic, and molecular investigations. J Pineal Res. 2000;28:156–64.

    CAS  PubMed  Google Scholar 

  249. Mulder H, Nagorny CL, Lyssenko V, Groop L. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia. 2009;52:1240–9.

    CAS  PubMed  Google Scholar 

  250. Picinato MC, Haber EP, Carpinelli AR, Cipolla-Neto J. Daily rhythm of glucose-induced insulin secretion by isolated islets from intact and pinealectomized rat. J Pineal Res. 2002;33:172–7.

    CAS  PubMed  Google Scholar 

  251. Peschke E, Hofmann K, Ponicke K, Wedekind D, Muhlbauer E. Catecholamines are the key for explaining the biological relevance of insulin-melatonin antagonisms in type 1 and type 2 diabetes. J Pineal Res. 2012;52:389–96.

    CAS  PubMed  Google Scholar 

  252. Nieuwenhuis RF, Spooren PF, Tilanus JJ. Less need for insulin, a surprising effect of phototherapy in insulin-dependent diabetes mellitus. Tijdschr Psychiatr. 2009;51:693–7.

    CAS  PubMed  Google Scholar 

  253. Terry PD, Goyal A, Phillips LS, Superak HM, Kutner MH. Design and rationale of a randomized controlled trial of melatonin supplementation in men and women with the metabolic syndrome. Open Access J Clin Trials. 2013;5:51–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Physiology, Department of Biomedical Science, Faculty of Medicine and Health Sciences, University of Stellenbosch, 19063, Tygerberg, 7505, Republic of South Africa

    Frederic Nduhirabandi B MedSc, B (Hons) Med Bio Sc, MSc MedSc & Amanda Lochner MSc, DSc, PhD

Authors
  1. Frederic Nduhirabandi B MedSc, B (Hons) Med Bio Sc, MSc MedSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amanda Lochner MSc, DSc, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frederic Nduhirabandi B MedSc, B (Hons) Med Bio Sc, MSc MedSc .

Editor information

Editors and Affiliations

  1. Sri Sathya Sai Medical Educational and Research Foundation, An International Medical Sciences Research Center, Coimbatore, Tamil Nadu, India

    V. Srinivasan

  2. Department of Obstetrics and Gynecology, Hadassah Hebrew-University Medical Center, Jerusalem, Israel

    Amnon Brzezinski

  3. Department of Physiology, Gulhane Military Medical Academy, Ankara, Turkey

    Sukru Oter

  4. Department of Psychiatry Behavioral Sciences, Mercer University School of Medicine, Macon, Georgia, USA

    Samuel D. Shillcutt

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer India

About this chapter

Cite this chapter

Nduhirabandi, F., Lochner, A. (2014). Melatonin and the Metabolic Syndrome. In: Srinivasan, V., Brzezinski, A., Oter, S., Shillcutt, S. (eds) Melatonin and Melatonergic Drugs in Clinical Practice. Springer, New Delhi. https://doi.org/10.1007/978-81-322-0825-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-0825-9_6

  • Published:

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-0824-2

  • Online ISBN: 978-81-322-0825-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation